Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The initiative was announced at World Hypertension Congress, Chennai
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
For the full year FY25, net profit soared 12x to Rs 345 crore
Subscribe To Our Newsletter & Stay Updated